Published in Eur J Nucl Med Mol Imaging on March 01, 2008
Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease. Eur J Nucl Med Mol Imaging (2013) 1.44
Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol (2013) 0.81
Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions. World J Radiol (2016) 0.75
Evaluation of radiographic and metabolic changes in bone metastases in response to systemic therapy with (18)FDG-PET/CT. Radiol Oncol (2015) 0.75
Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics (1999) 4.07
CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res (2004) 2.51
Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol (1998) 1.94
A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol (1997) 1.92
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology (1996) 1.72
Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol (2001) 1.66
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology (2002) 1.57
Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med (1999) 1.53
Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. J Nucl Med (1990) 1.42
Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging (2002) 1.28
Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat (2005) 1.24
Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med (2007) 1.21
Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm (2003) 1.20
18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol (1998) 1.19
Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol (1998) 1.17
Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med (2004) 1.16
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer (2004) 1.10
The role of positron emission tomography in the management of bone metastases. Cancer (2000) 1.10
CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology (2005) 1.10
Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr (1999) 1.06
Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med (2007) 1.06
Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol (1990) 1.05
The role of positron emission tomography in skeletal disease. Semin Nucl Med (2001) 1.04
Metastases: mechanisms, pathways, and cascades. AJR Am J Roentgenol (1995) 1.04
Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am (2005) 1.03
Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am (2004) 1.02
The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett (2005) 1.01
Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am (2004) 0.96
The presence of tumor cells in bone marrow at the time of first recurrence of breast cancer. Cancer (1987) 0.93
The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study. Eur J Nucl Med (1993) 0.93
FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy. Curr Opin Oncol (2004) 0.90
Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med (1998) 0.87
Radionuclide diagnosis of vertebral osteomyelitis: indium-111-leukocyte and technetium-99m-methylene diphosphonate bone scintigraphy. J Nucl Med (1991) 0.87
PET: a revolution in medical imaging. Radiol Clin North Am (2004) 0.85
A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol (2004) 0.84
Bone marrow and not bone is the primary site for skeletal metastasis: critical role of [18F]fluorodeoxyglucose positron emission tomography in this setting. J Clin Oncol (2007) 0.83
Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. Clin Radiol (2000) 0.82
Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet (1989) 0.81
Malignant lymphoma: bone marrow imaging versus biopsy. Radiology (1989) 0.81
Bone marrow MRI: techniques and accuracy for detecting breast cancer metastases. Magn Reson Imaging (1994) 0.81
Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma. J Clin Oncol (1997) 0.79
Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med (2002) 0.75
Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer. Clin Positron Imaging (2000) 0.75
Technetium-99m-labeled antigranulocyte antibody bone marrow scintigraphy. J Nucl Med (1995) 0.75
Bone marrow immunoscintigraphy compared with conventional bone scintigraphy for the detection of bone metastases. Acta Oncol (1993) 0.75
Bone marrow scintigraphy in lung carcinomas using nanosized colloids: when is it useful and how useful is it? Nucl Med Commun (1992) 0.75
Degenerative disc disease in the lumbar spine: another cause for focally reduced activity on marrow scintigraphy. Skeletal Radiol (1992) 0.75
Scintigraphy with nanocolloid Tc 99m in patients with small cell lung cancer, with special reference to bone marrow and hepatic metastasis. Eur J Nucl Med (1990) 0.75
Bone marrow scintigraphy in Paget's disease of bone. Acta Radiol (1990) 0.75
Bone marrow scintigraphy in breast cancer. Nucl Med Commun (1989) 0.75
Detection of bone marrow involvement in patients with cancer. Tumori (1989) 0.75
Bone and marrow imaging: do we know what we see and do we see what we want to know? Eur J Nucl Med Mol Imaging (2007) 0.75
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain (2005) 6.81
Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med (2007) 3.08
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging (2008) 2.74
18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med (2002) 2.45
Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med (2002) 2.05
Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging (2007) 1.93
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr (2007) 1.92
Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 1.88
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol (2005) 1.84
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Utility of FDG-PET scanning in lymphoma by WHO classification. Blood (2003) 1.69
Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol (2013) 1.66
PET in the management of urologic malignancies. Radiol Clin North Am (2004) 1.62
Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med (2002) 1.60
Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci (2006) 1.57
Assessment of atherosclerosis in large vessel walls: A comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification. J Nucl Cardiol (2015) 1.53
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med (2009) 1.52
Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med (2009) 1.51
An original case of isolated unilateral adrenal metastasis from penile carcinoma: documentation by 18F-FDG-PET imaging and histopathology. Hell J Nucl Med (2010) 1.49
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48
Is PET-CT the only option? Eur J Nucl Med Mol Imaging (2007) 1.48
The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med (2007) 1.47
Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma (2004) 1.44
Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease. Eur J Nucl Med Mol Imaging (2013) 1.44
Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med (2009) 1.44
Metabolic activity of the tongue in obstructive sleep apnea. A novel application of FDG positron emission tomography imaging. Am J Respir Crit Care Med (2014) 1.43
Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol (2009) 1.42
A pilot study to assess the utility of SPECT/CT-based lymph node imaging to localize lymph nodes that drain the arm in patients undergoing treatment for breast cancer. Breast Cancer Res Treat (2009) 1.42
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement (2011) 1.41
Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am (2005) 1.40
Splinting of penis following microvascular reconstruction-A simple inexpensive method. Indian J Plast Surg (2009) 1.39
FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med (2005) 1.38
When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging (2013) 1.37
Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging (2002) 1.37
Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med (2005) 1.33
Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun (2009) 1.31
18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med (2004) 1.31
Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol (2008) 1.30
In vivo detection of stem cells grafted in infarcted rat myocardium. J Nucl Med (2005) 1.30
Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med (2006) 1.28
Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat (2006) 1.27
Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging (2011) 1.27
Concurrent CBF and CMRGlc changes during human brain activation by combined fMRI-PET scanning. Neuroimage (2005) 1.26
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab (2007) 1.25
FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. Eur J Nucl Med Mol Imaging (2008) 1.25
Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med (2002) 1.23
Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med (2007) 1.21
Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med (2004) 1.19
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Commun (2007) 1.19
Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med (2004) 1.16
Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev (2008) 1.16
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med (2011) 1.14
FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging (2009) 1.13
FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging (2007) 1.13
A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med (2009) 1.12
FDG-PET findings in patients with suspected encephalitis. Clin Nucl Med (2004) 1.11
Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol (2009) 1.11
Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am (2005) 1.10
Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med (2003) 1.10
Comment on: "Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT". J Nucl Med (2013) 1.10
Incidental inflammatory findings in nerves and in patients with neoplastic diseases evaluated by 18F-FDG-PET/CT. Hell J Nucl Med (2009) 1.10
Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin (2007) 1.10
Underestimated role of 18F-FDG PET for HCC evaluation and promise of 18F-FDG PET/MR imaging in this setting. J Nucl Med (2013) 1.09
18FDG-positron emission tomography (PET) has a role to play in the diagnosis and therapy of infective endocarditis and cardiac device infection. Int J Cardiol (2013) 1.09
Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging (2007) 1.08
PET/MR imaging: technical aspects and potential clinical applications. Radiology (2013) 1.08
18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med (2004) 1.08
Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma. Curr Opin Oncol (2005) 1.07
Retracted Neuroradiological advances detect abnormal neuroanatomy underlying neuropsychological impairments: the power of PET imaging. Eur J Nucl Med Mol Imaging (2013) 1.06
Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications. J Nucl Med (2010) 1.06
18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: the early metabolic response is the answer. Eur J Cancer (2013) 1.06
Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Semin Nucl Med (2007) 1.06
Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med (2007) 1.06
FDG uptake in intercostal muscles is an indicator of severe respiratory disease. Clin Nucl Med (2004) 1.05
A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging (2011) 1.04
18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med (2002) 1.04
Diagnosis of pneumonia with an electronic nose: correlation of vapor signature with chest computed tomography scan findings. Laryngoscope (2004) 1.04
PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med (2004) 1.04